Lustgarten Foundation
Lustgarten Foundation
Explore linked clinical trials.12 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy | Pancreatic Adenocarcinoma Metastatic | Recruiting | Phase 2 | 2026-10-02 | NCT06747845 | |
| Promoting CT Engagement for Pancreatic Cancer With App | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Not applicable | 2026-09-16 | NCT06252545 | |
| Monitoring and Managing Glucose Levels in People With Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Nutritional and Metabolic Diseases, endocrine system disorder, glucose metabolism disease, hyperglycemia, malignant endocrine neoplasm, malignant pancreatic neoplasm, metabolic disease, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Not applicable | 2026-09-14 | NCT05132244 | |
| FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer | pancreatic adenocarcinoma | Active, not recruiting | Phase 2 | 2026-09-11 | NCT05077800 | |
| Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC | Digestive System Diseases, Digestive System Neoplasms, Fanconi anemia complementation group D1, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Not yet recruiting | Phase 2 | 2026-08-14 | NCT07765836 | |
| GENetic Education Risk Assessment and TEsting Study | Candidates for Hereditary Pancreatic Cancer Testing | Active, not recruiting | Not applicable | 2026-07-01 | NCT03762590 | |
| A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 1 | 2026-06-26 | NCT07671339 | |
| Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer | pancreatic ductal adenocarcinoma | Recruiting | Phase 2 | 2026-06-10 | NCT07199764 | |
| NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 | 2026-05-05 | NCT06941857 | |
| ZN-c3 + Gemcitabine in Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm | Active, not recruiting | Phase 2 | 2026-05-04 | NCT06015659 | |
| Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-12-03 | NCT06782932 | |
| Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Active, not recruiting | Phase 2 | 2025-10-01 | NCT03563248 |